Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects

Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects

Item
http://www.wikidata.org/entity/Q33802781
Liver enzymes elevation and immune reconstitution among treatment-naïve HIV-infected patients instituting antiretroviral therapy.Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women.Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in patients with pancreatic cancer.Darunavir and ritonavir total and unbound plasmatic concentrations in HIV-HCV-coinfected patients with hepatic cirrhosis compared to those in HIV-monoinfected patientsA review of nelfinavir for the treatment of HIV infection.Management and treatment of hepatitis C virus in patients with HIV and hepatitis C virus coinfection: A practical guide for health care professionals.Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosisInfluence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite.Drug disposition in pathophysiological conditions.Effect of Liver Disease on Hepatic Transporter Expression and Function.Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products.The effect of ravuconazole on the pharmacokinetics of nelfinavir in healthy male volunteers.Influence of chronic hepatitis C infection on cytochrome P450 3A4 activity using midazolam as an in vivo probe substrate.Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct-Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications.A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease.
P2860

Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects

Item
http://www.wikidata.org/entity/Q33802781
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Clinical pharmacokinetics of n ...... is C virus-coinfected subjects
@ast
Clinical pharmacokinetics of n ...... is C virus-coinfected subjects
@en
type
label
Clinical pharmacokinetics of n ...... is C virus-coinfected subjects
@ast
Clinical pharmacokinetics of n ...... is C virus-coinfected subjects
@en
prefLabel
Clinical pharmacokinetics of n ...... is C virus-coinfected subjects
@ast
Clinical pharmacokinetics of n ...... is C virus-coinfected subjects
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P921
P932
P356
P1433
P1476
Clinical pharmacokinetics of n ...... is C virus-coinfected subjects
@en
P2093
P2860
P304
P31
P356
10.1128/AAC.49.2.643-649.2005
P407
P433
P478
P577
P5875
P698
P921
P932